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Abstract
Background: Inhalation of particles aggravates respiratory symptoms including mucus hypersecretion in patients
with chronic airway disease and induces goblet cell hyperplasia (GCH) in experimental animal models. However,
the underlying mechanisms remain poorly understood.
Methods: To understand this, the numbers of goblet cells, Muc5ac (+) expressing epithelial cells and IL-13
expressing mast cells were measured in the trachea of sham or TiO2 particles – treated rats using periodic acid-
Schiff, toluidine blue and immunohistochemical staining. RT-PCR for Muc-1, 2 and 5ac gene transcripts was done
using RNA extracted from the trachea. Differential cell count and IL-13 levels were measured in bronchoalveolar
lavage (BAL) fluid. In pretreatment groups, cyclophosphamide (CPA) or dexamethasone (DEX) was given before
instillation of TiO2. TiO2 treatment markedly increased Muc5ac mRNA expression, and Muc5ac (+) or PAS (+)
epithelial cells 48 h following treatment.
Results: The concentration of IL-13 in BAL fluids was higher in TiO2 treated – rats when compared to those in
sham rats (p < 0.05). Pretreatment with cyclophosphamide (CPA) decreased the number of neutrophils and
eosinophils in BAL fluid of TiO2 treated – rats (p < 0.05), but affected neither the percentage of PAS (+) cells, nor
IL-13 levels in the BAL fluids (p > 0.05). In contrast, pretreatment with dexamethasone (DEX) diminished the
percentage of PAS (+) cells and the levels of IL-13 (p < 0.05). TiO2 treatment increased the IL-13 (+) mast cells
(p < 0.05) in the trachea, which was suppressed by DEX (p < 0.05), but not by CPA pretreatment (p > 0.05). In
addition there were significant correlations of IL-13 (+) rate of mast cells in the trachea with IL-13 concentration
in BAL fluid (p < 0.01) and with the percentage of Muc5ac (+) cells in the sham and TiO2 treated rats (p < 0.05).
Conclusion: In conclusion, TiO2 instillation induces GCH and Muc5ac expression, and this process may be
associated with increased production of IL-13 by mast cells.
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Background
Excessive mucus secretion is one of the major clinical
manifestations of chronic airway diseases such as asthma,
chronic bronchitis, and cystic fibrosis [1]. The excessive
mucus is attributed to goblet cell hyperplasia (GCH) and
submucosal gland hypertrophy, which are hallmarks of
airway remodeling in chronic airway diseases [2,3]. Air
pollution aggravates respiratory symptoms in patients
with chronic airway diseases. Chronic obstructive pulmo-
nary disease (COPD) patients living in communities
exposed to high levels of air pollution have faster rates of
decline in lung function than patients living in areas with
low pollution [4]. The level of environmental particles is
also positively correlated with exacerbation of asthma [5].
Airborne particulate matter less than 10 µm in aerody-
namic diameter (PM10) is a complex mixture of organic
and inorganic compounds containing sulfates and various
metals such as aluminum, calcium, copper, iron, lead,
magnesium, titanium, and zinc [6]. Clinically, PM10 par-
ticles are thought to provoke airway inflammation with
the release of mediators that are capable of exacerbating
lung disease in susceptible individuals [5,7]. This assump-
tion is based on experimental evidence of airway inflam-
mation following direct instillation or inhalation of PM10
particles in animal models [8]. Furthermore, inhaled par-
ticles directly stimulate macrophages and epithelial cells
to produce inflammatory cytokines such as TNF-α , GM-
CSF and IL-8 [9,10], which induce neutrophil- and eosi-
nophil-mediated airway inflammation, and eventually
lead to GCH. Recently, particle exposure favors the anti-
gen – sensitized lung toward Th2 environment with over
secretion of IL-13, IL-4 [11] and IL-5 [12]. Beside the
inflammatory cell mediated – GCH, IL-13 directly induces
GCH and Muc5AC gene expression through the signaling
of IL-4Rα  and IL-13Rα  [13,14]. Therefore, we hypothe-
sized that particles induce GCH via over-production of IL-
13 by recruited inflammatory cells.
Titanium dioxide (TiO2) particles, one component of
PM10, are found in dusty workplaces such as industries
involved in the crushing and grinding of the mineral ore
rutile [15]. It was reported that 50% of TiO2-exposed
workers had respiratory symptoms accompanied by
reduction in pulmonary function [16]. Because acute and
chronic exposure to TiO2 particles induces inflammatory
responses in the airways and alveolar spaces of rats
[17,18], TiO2 – instilled rat may be a good model to study
the particle induced – airway injury. In this study, we eval-
uated the role of neutrophilic and eosinophilic inflamma-
tion by pretreatment with cyclophosphamide inducing
neutropenia [19] and the association of IL-13 by pretreat-




Particles of TiO2 (mean diameter = 0.29 µm, DuPont,
Wilmington, DE) were suspended in endotoxin-free
saline. The endotoxin concentration of the TiO2 suspen-
sion was less than <0.32 EU/ml as measured with a limu-
lus amebocyte lysate kit (QCL-1000; BioWhittaker, Inc.,
Walkersville, MD). Seven-week-old male Sprague-Dawley
rats (Charles River Technology Inc.) received a single
intratracheal instillation of homogeneous suspension of
TiO2 particles (4 mg/kg in 200 µl of endotoxin free water).
In a pretreatment group, cyclophosphamide (CPA) (100
mg/kg, i.p.) was given 5 days before instillation of TiO2
and a second injection of CPA (50 mg/kg, i.p.) 1 day
before TiO2  instillation. In the second pretreatment
group, dexamethasone (DEX) (0.25 mg/kg, i.p.; Sigma, St.
Louis, MO) was administered 24 h before TiO2 instilla-
tion. The Institutional Animal Care and Use Committee
of Soonchunhyang University approved the study
protocols.
Preparation of lung tissues and morphological analysis
Rats were sacrificed at 4, 24, 48 and 72 hr after TiO2 instil-
lation by being anesthetized with pentobarbital sodium
(65 mg/kg, i.p.) and bronchoalveolar lavage (BAL) was
performed by 5 times instillation of 1 ml normal saline
and gentle retrieval. Cell numbers were measured using a
hemacytometer and differential cell counts were per-
formed on slides prepared by cyto-centrifugation and
Diff-Quik staining (Scientific Products, Gibbstowne, NJ).
Immediately following BAL, the trachea was snap-frozen
for RNA extraction or fixed with 4% paraformaldehyde in
PBS and embedded in paraffin. The tissues were subjected
to periodic acid-Schiff (PAS) and toluidine blue staining
to permit measurement of goblet cells and mast cells,
respectively. Morphometric analysis was performed under
light microscopy at ×400 magnification. PAS positive epi-
thelial cells and total epithelial cells were counted on the
length of 250 µm basement membrane at each of four pre-
determined sites (12, 3, 6, 9 o'clock; 12 o'clock was the
membranous portion) using a soft program (Nikon DXM
1200, Nikon Inc. N.Y. USA & Image Pro Plus 4.01 soft-
ware, Media Cybernetics, Maryland, USA). Results are
expressed as the percentage of goblet cells among the epi-
thelial cells. Mast cells in the airway wall were counted on
the membranous portion. The results are expressed as the
number of cells staining positive for toluidine blue per
area of 0.01 mm2.
Reverse transcription-polymerase chain reaction (RT-
PCR)
Total RNA was isolated using the modified guanidium thi-
ocyanate-phenol-chloroform extraction method [21].
DNase I (10,000 U/ml; Stratagene, La Jolla, CA)-treated
RNA was reverse-transcribed by incubating with 0.5 mMRespiratory Research 2005, 6:34 http://respiratory-research.com/content/6/1/34
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dNTP, 2.5 mM MgCl2, 5 mM DTT, 1 µl of random hex-
amer (50 ng/µl) and SuperScript II RT (200 unit/µl; Life
Technologies, Grand Island, NY) at 42°C for 50 min, and
heat inactivated at 70°C for 15 min. cDNA was aliquoted
into tubes containing specific primer pairs for rat GAPDH,
Muc1, Muc2 and Muc5ac genes for amplification (300,
403, 421, and 382-bp fragments, respectively). Nucle-
otide sequences of the primers were as follows. GAPDH-
forward ; 5'GGCATTGCTCTCAATGACAA3', GAPDH-
reverse; 5'AGGGCCTCTCTCTTGCTCTC3', Muc1-forward;
5' AGAGCTATGGGCAGCTGG 3', Muc1-reverse; 5' ACT-
ACCCCAGTGTCCCTC 3', Muc2-forward; 5' TACTGCT-
GATGACTGTAT 3', Muc2-reverse;
5'GGCCACAGGCCTGATACT3', Muc5ac-forward; 5'
TACAAGCCTGGTGAGTTC 3', Muc5ac-reverse; 5'
TCACAGTGCAGCGTCACA 3'. Amplification was per-
formed for 40 cycles (one cycle: 1 min at 94°C, 1 min at
52°C, and 1 min at 72°C) with initial denaturation at
94°C for 5 min and a final extension at 72°C for 10 min.
Immunohistochemical identification of Muc5ac-
expressing epithelial cells and IL-13-expressing cells
Muc5ac-positive (+) epithelial cells and IL-13-positive (+)
cells were identified by immunohistochemical staining.
Three-micron tissue sections of the trachea were treated
with 0.3% H2O2-methanol for 20 min to block endog-
enous peroxidase, and then incubated at 4°C overnight
with anti-rat Muc5ac mouse monoclonal antibody (1:200
dilution; Neomarkers, Fremont, CA) or biotinylated anti-
rat IL-13 antibody (1:5 dilution; Biosource, Camarillo,
CA). After the slides had been incubated with avidin-
biotin peroxidase complex (ABC kit, Vector Laboratories,
Burlingame, CA), color was developed with 3,3'-diami-
nobenzidine tetrachloride (DAB, Zymed Laboratories,
South San Francisco, CA). The Muc5ac expressing epithe-
lial cells and total epithelial cells were counted on the
length of 250 µm epithelial basement membrane at each
of four predetermined sites (12, 3, 6, 9 o'clock; 12 o'clock
was the membranous portion). Results are expressed as
the percentage of Muc5ac (+) cells among the epithelial
cells. IL-13 (+) cells was counted on the membranous por-
tion in the same way as mast cells were counted. The
results are expressed as the positive rate of mast cells for
IL-13 stain per area of 0.01 m2.
Measurement of IL-13 concentration in BAL fluids
The levels of IL-13 in the BAL fluids were measured with a
quantitative sandwich enzyme-linked immunoassay kit
(Biosource, Camarillo, CA). The lower limit of detection
was approximately 1.5 pg/ml. Values below this limit
were considered as zero for statistical analysis. Inter- and
intra-assay coefficients of variance were less than 10%.
Statistical analysis
Differences between independent samples were com-
pared using the Spearman test for continuous data. If dif-
ferences were found significant, the Mann-Whitney U test
was applied to compare differences between two samples.
Differences were considered significant when the p value
was less than 0.05. Results are expressed as means ± stand-
ard error of the mean (SEM) unless otherwise stated. The
correlations were analyzed between the ratio of Muc5ac
(+) expressing epithelial cell and the concentration of IL-
13 in BAL fluid and the number of mast cell and the IL-13
positive rate of mast cells by Spearman's non-parametric
correlation using SPSS (version 10.0, Chicago, USA)
Results and Discussion
Expression of Muc gene transcripts in the trachea of TiO2 
or saline – instilled rats
Total RNA was extracted from the trachea 24 h following
treatment with saline or TiO2 and analyzed for Muc1,
Muc2, and Muc5ac transcripts by RT-PCR. As shown in
Figure 1, Muc1, Muc2 and Muc5ac mRNAs were practi-
cally undetectable in sham-treated rats. In contrast, TiO2
treatment markedly increased Muc5ac mRNA, but only
modestly increased Muc2 mRNA. Muc1 mRNA was not
seen in TiO2-treated rats.
The effect of TiO2 instillation on Muc5ac-positive and 
PAS-positive epithelial cells in trachea
Rats were given a single intratracheal instillation of saline
or TiO2 and the percentage of Muc5ac-positive (Muc5ac
(+)) and PAS-positive (PAS (+)) epithelial cells were
measured. At 24 h after saline instillation, almost no PAS
(+) or Muc5ac (+) epithelial cells were found in the tra-
chea (Fig. 2Aa, b). TiO2 instillation, however, induced PAS
(+) or Muc5ac (+) cells in the trachea at 24 h (Fig. 2Ac, d).
The percentage of Muc5ac (+) cells was significantly
higher at 24 hr (p < 0.05) and further increased (Fig. 2B)
in TiO2 – instilled rats and maintained until 72 h when
compared with those of sham rats (p < 0.01). The percent-
age of PAS (+) cells was very similar to that of Muc5ac (+)
cells at 48 h after TiO2 instillation (Figure 2B).
Effects of cyclophosphamide and dexamethasone on the 
number of inflammatory cells and IL-13 levels in BAL fluid 
of TiO2-treated rats
The numbers of eosinophils and neutrophils are markedly
increased in the BAL fluids at 48 h after TiO2 instillation
when compared with those in saline-treated rats (p < 0.05,
respectively) (Fig. 3A and 3B). Also, the levels of IL-13 in
BAL fluids were significantly higher in TiO2 – treated rats
than those of sham rats at 48 h after treatment (p < 0.05)
(Fig. 3D). Pretreatment with CPA prior to TiO2 instillation
significantly decreased the numbers of neutrophils and
eosinophils in BAL fluids when compared with those in
rats at 48 h after treatment with TiO2 alone (p < 0.05, Fig.Respiratory Research 2005, 6:34 http://respiratory-research.com/content/6/1/34
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3A &3B). Pretreatment with CPA, however, did not affect
both the ratio of PAS (+) cells in the trachea and the IL-13
levels in BAL fluids of TiO2-treated rats (p > 0.05, Fig. 3C
&3D). Pretreatment with DEX prior to TiO2 instillation
significantly decreased the number of eosinophils in BAL
fluid (p < 0.05, Fig. 3A), the ratio of PAS (+) cells in the
trachea (p < 0.05, Fig 3C) and the levels of IL-13 in BAL
fluid (p < 0.05, Fig. 4D) compared with those of rats
instilled by TiO2 alone.
Effects of cyclophosphamide and dexamethasone on the 
number and IL-13 expression of mast cells in TiO2-treated 
rats
Toluidine blue – stained mast cells were observed in and
around the muscle layer of the trachea in saline-treated
rats. The shape of the cells was relatively round with a sin-
gle nucleus and a large cytoplasm containing granules
(Fig. 4Ab). In TiO2-instilled rats, some mast cells showed
an elongated and branching shape of the cytoplasm (Fig.
4Bb). The trachea of the saline-treated group contained no
IL-13 (+) cells (Fig. 4Aa) in spite of the presence of mast
cells (Fig. 4Ab). TiO2-instilled rats increased the number
of mast cells when compared with the saline control
group (p < 0.05, Figs. 4Bb and 4E). Serial section slides of
the trachea showed that IL-13 protein was expressed
exclusively on the mast cells in TiO2 – treated rats (Fig.
4Ba). CPA pretreatment did not affect the TiO2-induced
increase in the number of toluidine blue (+) mast cells
positive for IL-13 (p > 0.05, Fig. 4Ca, 4Cb &4E). However,
DEX pretreatment significantly decreased the number of
toluidine blue (+) mast cells expressing IL-13 compared to
those of TiO2 – treated rats (p < 0.05, Fig. 4Da, 4Db &4E).
The correlation between the number of IL-13 expressing 
mast cells, the concentration of IL-13 in BAL and Muc 5ac 
positive epithelial cells in the airway
The number of mast cells in the trachea was significantly
correlated with percentage of Muc5ac (+) epithelial cells
and concentration of IL-13 in BAL fluid of TiO2 – treated
(n = 7) and sham (n = 6) rats (p < 0.001 and p < 0.0001,
respectively, Table 1). However, the number of eosinophil
and neutrophils in BAL fluids were correlated with neither
the percentage of Muc5ac (+) epithelial cells nor the con-
centration of IL-13 in BAL fluid (p > 0.05, Table 1). In
addition, there were significant correlations of IL-13 (+)
rate of mast cells in the trachea with IL-13 concentration
in BAL fluid (r = 0.782, p < 0.01, Fig. 5A) and with the per-
centage of Muc5ac (+) cells in the sham and TiO2 treated
rats (r = 0.604, p < 0.05, Fig 5B).
Discussion
Although air pollution contains heavy metallic environ-
mental particles that increases morbidity and mortality of
the patients with chronic airway diseases [4,5], the under-
lying mechanisms of mucus hyperproduction causing air-
way obstruction has not been revealed in detail. In this
study, we demonstrated that a single instillation of TiO2 is
able to induce GCH within 24 h. The TiO2-induced GCH
is associated with a dramatic increase in Muc5ac gene and
protein expression in the present study (Figure 1 &2). Up
regulation of Muc5ac gene in TiO2 – induced GCH is
thought to be a common pathway in the process of GCH
because MUC5AC has been demonstrated to be a major
MUC gene during the process of GCH observed in the
other non-particulates experimental model of airway dis-
eases [22-25] and the asthmatics [26]. GCH is known as
associated with airway inflammation and can be experi-
mentally induced by various inflammatory agents such as
LPS [22], neutrophil elastase [27], cathepsin B [23], IL-4
[25], IL-9 [28], and IL-13 [29,30].
The expression of Muc1, Muc2 and Muc5ac mRNA in TiO2  treated rats Figure 1
The expression of Muc1, Muc2 and Muc5ac mRNA in TiO2 
treated rats. Rats were treated with TiO2, as described in 
Methods. Twenty-four hours after treatment, the levels of 
the Muc gene transcripts in the trachea were quantified using 
RT-PCR. GAPDH was used to ensure an equal loading of 
RNA samples. This figure is representative of 4 experiments.Respiratory Research 2005, 6:34 http://respiratory-research.com/content/6/1/34
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The exact mechanism of GCH, however, may differ in the
experimental models. Neutrophils or eosinophils have
been implicated in the induction of GCH in some animal
models [30,31]. Neutrophils and eosinophils depleted
rats using CPA or specific antibodies inhibit granulocyte
in agarose plug-induced and IL-13-induced GCH model
[29,31]. The epidermal growth factor receptor cascades are
showed to be involved in underlying mechanism of the
neutrophils – induced GCH [29,31]. However, in the
present study we showed that depletion of these inflam-
matory cells by pretreatment with CPA similar dose used
in the previously study [29,31] did not prevent TiO2-
induced GCH (Figure 4). Because cyclophosphamide
effectively suppressed the number of neutrophils and
eosinophils in peripheral blood (data not shown) and air-
ways in the present study although not complete (Figure
4), our data indicates that these inflammatory cells may
be not responsible for the TiO2-induced GCH. The disso-
ciation of GCH from airway eosinophilia has been well
documented in murine asthma models, in which anti-IL-
5 (TRFK-5) [32], or IL-5 deficiency [33] reduced airway
eosinophilia without affecting the induction of GCH.
Therefore, depending on the experimental models investi-
gated, the induction of GCH may not require neutrophils
and eosinophils. Furthermore, IL-13 is known to induce
GCH without any help of other inflammatory cells [24]
and has been clearly shown to play a single, common
pathway by which GCH is induced by CD4+ cells and IL-
9 [34]. This process needs IL-4 receptor alpha, but not IL-
4 or IL-5 [33,34]. These data suggested a possibility that
IL-13 is also involved in the particle – induced GCH.
In the present study, the levels of IL-13 in BAL fluids
increased after TiO2 instillation concomitantly with the
development of GCH and the increase of IL-13 was com-
pletely abolished by pretreatment with DEX (0.25 mg/
Kg), but not by that with CPA (Figure 4). These results sug-
gest that the elevation of IL-13 may be associated with par-
ticles such as TiO2-induced GCH without any assistance of
neutrophils or eosinophils. The in vivo effect of dexame-
thasone has been also demonstrated in allergic asthma
model [35]. Dexamethasone (4 mg / kg) effectively abol-
ishes allergic airway inflammation in mice by suppression
of IL-13 m-RNA and protein expression [35]. The exact
Light microscopic analysis of the trachea and the percentage of Muc5ac, PAS (+) epithelial cells Figure 2
Light microscopic analysis of the trachea and the percentage of Muc5ac, PAS (+) epithelial cells. Rats were treated intratrache-
ally with saline or TiO2, and the tracheas were prepared for morphometric analysis of PAS (+) and Muc5ac (+) cells as 
described in Methods. A. Histology of trachea 24 hr after saline or TiO2 treatment. PAS (+) cells were stained red whereas 
Muc5ac (+) cells dark brown. Note that the trachea obtained from the saline-treated group contained little or no PAS (+) (Aa) 
or Muc5ac (+) cells (Ab) while the trachea from TiO2-treated group contains significant number of PAS (+) (Ac) and Muc5ac 
(+) cells (Ad). B. Time (4, 24, 48,72 h) dependent change in the percentage of Muc5ac (+) cells following saline (open bar, n = 
8) or TiO2 treatment (closed bar, n = 8). Note that the percentage of PAS (+) cells was similar to that of Muc5ac (+) cells at 48 
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biochemical mechanism of GCH induction by IL-13 is not
fully understood. One possible explanation is that IL-13
converts the bronchial epithelium from an absorptive to a
secretory phenotype through loss of an amiloride-sensi-
tive current and an increase in calcium-sensitive apical
anion conductance [36]. The increase in apical anion con-
ductance in the airway epithelium is most likely due to the
ability of IL-13 to induce expression of hCLCA1/
mCLCA3, which encodes a calcium-activated chloride
channel. This channel is necessary and sufficient for the
development of GCH and mucus hypersecretion in some
experiments [37].
Besides Th2 cells, IL-13 is produced by mast cells, eosi-
nophils [38,39], and macrophages [40]. Since IL-13 was
not decreased in rats of which eosinophils depleted by
pretreatment of CPA (Figure 4), we can exclude eosi-
nophils as the source of IL-13. Interestingly, serial thin
section slides revealed that the IL-13 positive cells are
mast cells, as shown by staining with toluidine blue. Also,
we found the significant correlation between the IL-13 (+)
rate of mast in tissue, concentration of IL-13 in BAL fluid
and Muc5ac positive cells (Figure 5 and table 1). Based on
these data, mast cells may be the cellular source for IL-13
present in the airways of TiO2-treated rats. It is well known
The cell distribution in BAL fluid of TiO2 instilled rats with or without pretreatment Figure 3
The cell distribution in BAL fluid of TiO2 instilled rats with or without pretreatment. Rats were pretreated with CPA (n = 6) or 
DEX (n = 6) and then treated intratracheally with TiO2. Saline (n = 8) or TiO2 (n = 8) was treated without pretreatment. At 48 
h post-treatment, BAL fluids were collected and analyzed for the numbers of eosinophils (A), neutrophils(B), and the levels of 
IL-13(D). PAS (+) cells (C) were measured in the trachea as described in Methods. * p < 0.05 as compared with saline – treated 
group, † p < 0.05 as compared with TiO2 – treated group.Respiratory Research 2005, 6:34 http://respiratory-research.com/content/6/1/34
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that mast cells produce IL-13 when stimulated with
antigen [39] and that the synthesis can be suppressed by
dexamethsone [20]. Our finding showed that TiO2 instil-
lation increased the numbers of IL-13 expressing mast
cells and Muc5ac (+) goblet cells, both of which were
decreased by dexamethsone pretreatment is a novel find-
ing to our knowledge. It is not known whether TiO2 –
induced IL-13 overproduction is specific to TiO2 or gener-
ally related to other particulates. However, base on the
findings of particles such as diesel exhaust particles or car-
bon black particle – induced the deviation to Th2 environ-
ment in antigen sensitized lung [11,12], TiO2 – induced
GCH via over production of IL-13 may be a general find-
ing attributed to the particulate matters, but it remains
unproven.
Conclusion
We demonstrated that a single intratracheal instillation of
TiO2 particles induces GCH and Muc5ac gene expression
within 24 h in rats, and that this process may be associated
The effects of cyclophosphamide (CPA) or dexamethasone (DEX) on the IL-13 (+) expressing cells Figure 4
The effects of cyclophosphamide (CPA) or dexamethasone (DEX) on the IL-13 (+) expressing cells. Rats were pretreated 
intratracheally with saline (Fig. A, E ; n = 8), CPA (Fig. C, E ; n = 6) or DEX (Fig. D, E ; n = 6) prior to treatment with TiO2 Eight 
rats were treated with TiO2 alone (Fig. B, E ; n = 8) as described in Methods. At 48 h post-treatment, IL-13 (+) cells are stained 
brown whereas toluidine blue (+) mast cells are stained dark purple. Note that saline – treated group contained little or no IL-
13 (+) cells (Aa) in spite of the presence of mast cells (Ab). TiO2-treated group showed significantly increasing numbers of mast 
cells when compared with sham group (E) and the mast cells (Ba) showed strong positivity for IL-13 protein (Bb). CPA pre-
treatment did not affect the TiO2 induced-increase in the number of IL-13 (+) cells (Ca) or mast cells (Cb & E). On the other 
hand, DEX pretreatment significantly decreased the number of mast cells (Db & E) and reduced the IL-13 (+) cells (Da). * p < 
0.05 as compared with saline treated group, † p < 0.05 as compared with TiO2 treated group.
Table 1: The correlation of Muc5ac(+) cells or the IL-13 concentration with the number of inflammatory cells. The correlation 
between percentage of Muc5ac (+) epithelial cells or concentration of IL-13 in BAL fluid and number of eosinophil, neutrophil and 
mast cell in sham (n = 6) and TiO2 – instilled rats (n = 7).
Correlation (ρ ) Eosinophils No. in BAL fluid Neutrophils No. in BAL fluid Mast cells No. in trachea
% of Muc5ac (+) 0.156 (p = 0.549) -0.195 (p = 0.438) 0.813 (p = 0.001*)
Concentration of IL-13 in BAL 
fluid
0.447 (p = 0.138) 0.193 (p = 0.57) 0.903 (p = 0.0001**)
* p < 0.05, ** p < 0.01Respiratory Research 2005, 6:34 http://respiratory-research.com/content/6/1/34
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with elevated amount of IL-13 derived from mast cells.
The present study may provide experimental evidences to
support that patients with chronic airway disease may
aggravate their symptoms and airway functions in the
heavily polluted environment of particulate matters.
Acknowledgements
The authors are indebted to Hwan-man Shin, Myong-ran Lee, and Eun-
young Kim for their excellent animal care and technical support throughout 
the study. The authors express thanks to at least two professional editors, 
both native speakers of English for their kind editing for grammar and top-
ographic error http://www.textcheck.com. This work was supported by a 
grant from the Korea Health 21 R&D Project, Ministry of Health and Wel-
fare, Republic of Korea (01-PJ3-PG6-01GN04-003).
References
1. Openshaw PJ, Turner-Warwick M: Observations on sputum pro-
duction in patients with variable airflow obstruction; Impli-
cations for the diagnosis of asthma and chronic bronchitis.
Respir Med 1989, 83:25-31.
2. Thurlbeck WM, Malaka D, Murphy K: Goblet cells in the periph-
eral airways in chronic bronchitis.  Am Rev Respir Dis 1975,
112:65-9.
3. Aikawa T, Shimura S, Sasaki H, Ebina M, Takishima T: Marked goblet
cell hyperplasia with mucus accumulation in the airways of
patients who died of severe acute asthma attack. Chest 1992,
101:916-21.
4. Pope CA, Kanner RE: Acute effects of PM10 pollution on pul-
monary function of smokers with mild to moderate chronic
obstructive pulmonary disease.  Am Rev Respir Dis 1993,
147:1336-40.
5. Schwartz J, Slater D, Larson TV, Pierson WE, Koenig JQ: Particulate
air pollution and hospital emergency room visits for asthma
in Seattle. Am Rev Respir Dis 1993, 147:826-31.
6. Pagan I, Costa DL, McGee JK, Richards JH, Dye JA: Metals mimic
airway epithelial injury induced by in vitro exposure to Utah
Valley ambient particulate matter extracts. J Toxicol Environ
Health A 2003, 66:1087-112.
7. Seaton A, MacNee W, Donaldson K, Godden D: Particulate air
pollution and acute health effects. Lancet 1995, 345:176-8.
8. Li XY, Gilmour PS, Donaldson K, MacNee W: Free radical activity
and pro-inflammatory effects of particulate air pollution
(PM10) in vivo and in vitro. Thorax 1996, 51:1216-1222.
9. Becker S, Soukup JM, Gilmour MI, Devlin RB: Stimulation of
human and rat alveolar macrophages by urban air particu-
lates: effects on oxidant radical generation and cytokine
production. Toxicol Appl Pharmacol 1996, 141:637-48.
10. Fujii T, Hayashi S, Hogg JC, Vincent R, Van Eeden SF: Particulate
matter induces cytokine expression in human bronchial epi-
thelial cells. Am J Respir Cell Mol Biol 2001, 25:265-71.
11. Hamilton RF Jr, Holian A, Morandi MT: A comparison of asbestos
and urban particulate matter in the in vitro modification of
human alveolar macrophage antigen-presenting cell
function. Exp Lung Res 2004, 30:147-62.
12. Li N, Hao M, Phalen RF, Hinds WC, Nel AE: Particulate air pollut-
ants and asthma, A paradigm for the role of oxidative stress
in PM-induced adverse health effects. Clinical Immunology 2003,
109:250-265.
13. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Whang Y, Elias
JA: Pulmonary expression of interleukin-13 causes inflamma-
tion, mucus hypersecretion, subepithelial fibrosis, physio-
logic abnormalities, and eotaxin production. J Clin Invest 1999,
103:779-788.
14. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Ren-
nick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry
DB: Requirement for IL-13 independently of IL-4 in experi-
mental asthma. Science 1998, 282:2261-3.
15. Templeton DM: Titanium. In handbook on metals in clinical and ana-
lytic chemistry Edited by: Seiler HG, Siegel A, Siegel H. New York: Mar-
cel Dekker; 1994:627-30. 
16. Garabrant DH, Fine LJ, Oliver C, Bernstein L, Peters JM: Abnormal-
ities of pulmonary function and pleural disease among tita-
nium metal production workers. Scand J Work Environ Health
1987, 13:47-51.
17. Schapira RM, Ghio AJ, Effros RM, Morrisey J, Almagro UA, Dawson
CA, Hacker AD: Hydroxyl radical production and lung injury in
the rat following silica or titanium dioxide instillation in vivo.
Am J Respir Cell Mol Biol 1995, 12:220-6.
18. Warheit DB, Hansen JF, Yuen IS, Kelly DP, Snajdr SI, Hartsky MA:
Inhalation of high concentrations of low toxicity dusts in rats
results in impaired pulmonary clearance mechanisms and
persistent inflammation. Toxicol Appl Pharmacol 1997, 145:10-22.
19. Nagai H, Yamaguchi S, Tanaka H, Inagaki N: Effect of some immu-
nosuppressors on allergic bronchial inflammation and airway
hyperresponsiveness in mice.  Int Arch Allergy Immunol 1995,
108:189-95.
20. Fushimi T, Okayama H, Shimura S, Saitoh H, Shirato K: Dexameth-
asone suppresses gene expression and production of IL-13 by
human mast cell line and lung mast cells. J Allergy Clin Immunol
1998, 102:134-42.
21. Chomczynski P, Sacchi N: Single-step method of RNA isolation
by acid guanidinium thiocyanate-phenol-chloroform
extraction. Anal Biochem 1987, 162:156-9.
22. Harkema JR, Hotchkiss JA: In vivo effects of endotoxin on
intraepithelial mucosubstances in rat pulmonary airways.
Quantitative histochemistry. Am J Pathol 1992, 141:307-17.
23. Cardozo C, Padilla ML, Choi HS, Lesser M: Goblet cell hyperplasia
in large intrapulmonary airways after intratracheal injection
of cathepsin B into hamsters.  Am Rev Respir Dis 1992,
145:675-679.
24. Kibe A, Inoue H, Fukurama S, Machida K, Matsumoto K, Koto H, Ike-
gami T, Aizawa H, Hara N: Differential regulation by glucocorti-
coid of interleukin-13-induced eosinophilia,
hyprresponsiveness, and goblet cell hyperplasia in mouse
airways. Am J Respir Crit Care Med 2003, 167:50-56.
25. Dabbagh K, Takeyama K, Lee HM, Ueki IF, Lausier JA, Nadel JA: IL-4
induces mucin gene expression and goblet cell metaplasia in
vitro and in vivo. J Immunol 1999, 162:6233-7.
26. Ordonez CL, Khashayar R, Wong HH, Ferrando R, Wu R, Hyde DM,
Hotchkiss JA, Zhang Y, Novikov A, Dolganov G, Fahy JV: Mild and
moderate asthma is associated with airway goblet cell
hyperplasia and abnormalities in mucin gene expression. Am
J Respir Crit Care Med 2001, 163:517-523.
27. Lucey EC, Stone PJ, Breuer R, Christensen TG, Calore JD, Catanese
A, Franzblau C, Snider GL: Effect of combined human neu-
trophil cathepsin G and elastase on induction of secretory
cell metaplasia and emphysema in hamsters, with in vitro
observations on elastolysis by these enzymes. Am Rev Respir Dis
1985, 132:362-6.
The correlation of the IL-13(+) mast cells with Muc5ac(+)  epithelial cells and the IL-13 concentration Figure 5
The correlation of the IL-13(+) mast cells with Muc5ac(+) 
epithelial cells and the IL-13 concentration. The percentage 
of IL-13 (+) mast cells was correlated with concentration of 
IL-13 in BAL fluid (r = 0.782, p < 0.01) and the percentage of 
Muc5ac (+) cells (r = 0.604, p < 0.05) (open circle; sham, 
open square; TiO2 – instilled rats).Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Respiratory Research 2005, 6:34 http://respiratory-research.com/content/6/1/34
Page 9 of 9
(page number not for citation purposes)
28. Townsend MJ, Fallon PG, Matthews DJ, Smith P, Jolin HE, McKenzie
ANJ: IL-9-deficient mice establish fundamental roles for IL-9
in pulmonary mastocytosis and goblet cell hyperplasia but
not T cell development. Immunity 2000, 13:573-583.
29. Shim JJ, Dabbagh K, Ueki IF, Dao-Pick T, Burgel PR, Takeyama K, Tam
DC, Nadel JA: IL-13 induces mucin production by stimulating
epidermal growth factor receptors and by activating
neutrophils. Am J Physiol Lung Cell Mol Physiol 2001, 280:L134-40.
30. Singer M, Lefort J, Vargaftig BB: Granulocyte depletion and dex-
amethasone differentially modulate airways hyperreactivity,
inflammation, mucus accumulation, and secretion induced
by rmIL-13 or antigen. Am J Respir Cell Mol Biol 2002, 26:74-84.
31. Lee HM, Takeyama K, Dabbagh K, Lausier JA, Ueki IF, Nadel JA: Aga-
rose plug instillation causes goblet cell metaplasia by activat-
ing EGF receptors in rat airways. Am J Physiol Lung Cell Mol Physiol
2000, 278:L185-92.
32. Mathur M, Herrmann K, Li X, Qin Y, Weinstock J, Elliott D, Monahan
J, Padrid P: TRFK-5 reverses established airway eosinophilia
but not established hyperresponsiveness in a murine model
of chronic asthma. Am J Respir Crit Care Med 1999, 159:580-7.
33. Cohn L, Homer RJ, MacLeod H, Mohrs M, Brombacher F, Bottomly
K: Th2-induced airway mucus production is dependent on IL-
4Ralpha, but not on eosinophils. J Immunol 1999, 162:6178-83.
34. Whittaker L, Niu N, Temann UA, Stoddard A, Flavell RA, Ray A,
Homer RJ, Cohn L: Interleukin-13 mediates a fundamental
pathway for airway epithelial mucus induced by CD4 cells
and interleukin-9. Am J Respir Cell Mol Biol 2002, 27:593-602.
35. Eum SY, Maghni K, Hamid Q, Eidelman DH, Campbell H, Isogai S,
Martin JG: Inhibition of allergic airways inflammation and air-
way hyperresponsiveness in mice by dexamethasone : Role
of eosinophils, IL-5, eotaxin, and IL-13. J Allergy Clin Immunol
2003, 111:1049-61.
36. Danahay H, Atherton H, Jones G, Bridges RJ, Poll CT: Interleukin-
13 induces a hypersecretory ion transport phenotype in
human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol
2002, 282:L226-36.
37. Zhou Y, Dong Q, Louahed J, Dragwa C, Savio D, Huang M, Weiss C,
Tomer Y, McLane MP, Nicolaides NC, Levitt RC: Characterization
of a calcium-activated chloride channel as a shared target of
Th2 cytokine pathways and its potential involvement in
asthma. Am J Respir Cell Mol Biol 2001, 25:486-91.
38. Wills-Karp M, Chiaramonte M: Interleukin-13 in asthma.  Curr
Opin Pulm Med 2003, 9:21-7.
39. Burd PR, Thompson WC, Max EE, Mills FC: Activated mast cells
produce interleukin 13. J Exp Med 1995, 181:1373-80.
40. Hancock A, Lynne Armstrong , Rafael Gama , Ann Millar : Produc-
tion of Interleukin 13 by alveolar macrophages from normal
and fibrotic lung. Am J Respir Cell Mol Biol 1998, 18:60-65.